214822-96-5

Basic information

• Product Name: METHYL 4-FLUORO-3-HYDROXYBENZOATE
• Synonyms: METHYL 4-FLUORO-3-HYDROXYBENZOATE;Methyl 4-fluoro-3-hydroxybenzoate, 98+%;4-Fluoro-3-hydroxybenzoic Acid Methyl Ester;2-Fluoro-5-(methoxycarbonyl)phenol
• CAS NO: 214822-96-5
• Molecular Formula: C₈H₇FO₃
• Molecular Weight: 170.14
• Product Categories: Aromatic Esters;Phenylacetic acid;Acids & Esters;Fluorine Compounds;Phenols
• Mol File: 214822-96-5.mol
• Article Data: 18

Chemical Properties

• Melting Point: 89-91°C
• Boiling Point: 268.9 °C at 760 mmHg
• Flash Point: 116.4 °C
• Appearance: /
• Density: 1.309 g/cm³
• Solubility: soluble in Methanol
• PKA: 7.89±0.10(Predicted)
• CAS DataBase Reference: METHYL 4-FLUORO-3-HYDROXYBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-FLUORO-3-HYDROXYBENZOATE(214822-96-5)
• EPA Substance Registry System: METHYL 4-FLUORO-3-HYDROXYBENZOATE(214822-96-5)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 214822-96-5(Hazardous Substances Data)

Usage

General Description

METHYL 4-FLUORO-3-HYDROXYBENZOATE is a chemical compound with the molecular formula C8H7FO3. It is an ester derived from methyl alcohol and 4-fluoro-3-hydroxybenzoic acid. METHYL 4-FLUORO-3-HYDROXYBENZOATE is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has potential applications in the field of medicine and agriculture due to its structural properties. METHYL 4-FLUORO-3-HYDROXYBENZOATE is also used as a flavoring agent and in the production of fragrances. However, it is important to handle this chemical with care as it may pose health and environmental risks if not properly managed.

Upstream product

• 51446-31-2 4-fluoro-3-hydroxybenzoic acid 
• 149-73-5 trimethyl orthoformate 
• 757982-31-3 methyl 4-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 403-33-8 methyl 4-flurobenzoate 
• 67-56-1 methanol 

Downstream Products

• 909407-23-4 3-(2-carboxy-ethoxy)-4-fluoro-benzoic acid methyl ester 
• 934241-78-8 2-fluoro-5-(hydroxymethyl)phenol 
• 1446701-52-5 methyl 3-(3-bromopropoxy)-4-fluorobenzoate 
• 1615242-51-7 N-ethyl 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzamide 
• 1615242-50-6 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzamide 
• 1446711-81-4 3-[3-(3,5-dimethyl-1H-pyrazol-4-yl)-propoxy]-4-fluoro-benzoic acid 
• 1613413-37-8 [4-fluoro-3-[(4-fluorophenyl)methoxy]phenyl]methanol 
• 1613413-36-7 methyl 4-fluoro-3-[(4-fluorophenyl)methoxy]benzoate 
• 1307254-85-8 C₂₀H₂₆FNO₅ 
• 1268619-82-4 3-(2-chloropyridin-4-yloxy)-4-fluoro-N-(2-fluoro-5-methylphenyl)benzamide 
• 1268619-81-3 3-(2-chloropyridin-4-yloxy)-4-fluorobenzoic acid 
• 1268619-83-5 methyl 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate 
• 1268619-80-2 3-(2-chloropyridin-4-yloxy)-4-fluorobenzoic acid methyl ester 

Relevant articles and documents

Sequential Ir/Cu-Mediated Method for the Meta-Selective C-H Radiofluorination of (Hetero)Arenes

This article describes a sequential Ir/Cu-mediated process for the meta-selective C-H radiofluorination of (hetero)arene substrates. In the first step, Ir-catalyzed C(sp2)-H borylation affords (hetero)aryl pinacolboronate (BPin) esters. The intermediate organoboronates are then directly subjected to copper-mediated radiofluorination with [18F]tetrabutylammonium fluoride to afford fluorine-18 labeled (hetero)arenes in high radiochemical yield and radiochemical purity. This entire process is performed on a benchtop without Schlenk or glovebox techniques and circumvents the need to isolate (hetero)aryl boronate esters. The reaction was automated on a TracerLab FXFN module with 1,3-dimethoxybenzene and a meta-tyrosine derivative. The products, [18F]1-fluoro-3,5-dimethoxybenzene and an 18F-labeled meta-tyrosine derivative, were obtained in 37 ± 5% isolated radiochemical yield and >99% radiochemical purity and 25% isolated radiochemical yield and 99% radiochemical purity, and 0.52 Ci/μmol (19.24 GBq/μmol) molar activity (Am), respectively.

NOVEL INHIBITORS OF MAP4K1

The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative diseases, diseases of immune system dysfunction, inflammatory disorders, neurological diseases, and cardiovascular diseases. The invention further relates to pharmaceutical compositions comprising the same and methods of treatment of said diseases and disorders. The inhibitors are of formula (I) wherein the definitions for A, D, E, F, R5, R6, R7, Z, ring Q, n, x and y are as given in the application.

HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.